Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.

MLA

Yamazaki, Tomoko, et al. “Galunisertib plus Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Single-Arm, Phase 2 Trial.” The Lancet. Oncology, vol. 23, no. 9, Sept. 2022, pp. 1189–200. EBSCOhost, https://doi.org/10.1016/S1470-2045(22)00446-6.

APA

Yamazaki, T., Gunderson, A. J., Gilchrist, M., Whiteford, M., Kiely, M. X., Hayman, A., O’Brien, D., Ahmad, R., Manchio, J. V., Fox, N., McCarty, K., Phillips, M., Brosnan, E., Vaccaro, G., Li, R., Simon, M., Bernstein, E., McCormick, M., Yamasaki, L., … Young, K. H. (2022). Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. The Lancet. Oncology, 23(9), 1189–1200. https://doi.org/10.1016/S1470-2045(22)00446-6

Chicago

Yamazaki, Tomoko, Andrew J Gunderson, Miranda Gilchrist, Mark Whiteford, Maria X Kiely, Amanda Hayman, David O’Brien, et al. 2022. “Galunisertib plus Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Single-Arm, Phase 2 Trial.” The Lancet. Oncology 23 (9): 1189–1200. doi:10.1016/S1470-2045(22)00446-6.